Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. - Wikidata - wikimedia - TriplyDB

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

http://www.wikidata.org/entity/Q34263870

about

Targeting the Pim kinases in multiple myeloma V. Molecular classification and risk stratification of myeloma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Molecular pathogenesis of multiple myeloma: basic and clinical updates The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential TPL2 kinase regulates the inflammatory milieu of the myeloma niche Activity of 129 single-agent drugs in 228 phase I and II clinical trials in multiple myeloma.IAP antagonists induce anti-tumor immunity in multiple myeloma.Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS.First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.Non-invasive imaging provides spatiotemporal information on disease progression and response to therapy in a murine model of multiple myeloma.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma.Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma Molecular pathogenesis of multiple myeloma and its premalignant precursor.The novel mechanism of lenalidomide activity.Preclinical animal models of multiple myeloma FOXM1 is a therapeutic target for high-risk multiple myeloma.The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases.Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.Spontaneous onset and transplant models of the Vk*MYC mouse show immunological sequelae comparable to human multiple myeloma.Preclinical activity of melflufen (J1) in ovarian cancer.Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma.Diffuse large B cell lymphoma: molecular targeted therapy.Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.Preclinical models of multiple myeloma: a critical appraisal.The Tao of myeloma.Targeting the bone marrow microenvironment in multiple myeloma.Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.The molecular mechanism of thalidomide analogs in hematologic malignancies.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276.Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma.

P2860

Q26799499-93D365BF-9901-4F5F-BFA1-7C930C9CF7AA Q26861396-FB45C671-3030-463E-A18E-F69C12EEC25F Q27004421-4058CDA5-6444-430E-8682-80705B9F82EB Q27026205-13AB8E34-ED49-4D47-8D0B-F7A960EC018F Q28075927-0FB42CC1-F038-404D-AD52-A4B092869F11 Q33714724-3C0679AA-1AA9-45D2-9079-E5AB14470A13 Q33882439-F1AEFB4B-F813-4C83-BC6F-EBAB1EBD5C59 Q33914862-7B8727AF-99B7-498D-B73C-0190851537BC Q34483086-DF3F236F-57AF-404A-B59C-1BF15B5291F3 Q34501199-7FAD9957-BD5E-4F05-A9C2-2D7707DAB081 Q34540657-6D078731-732E-4613-BFEC-BF666FD8B63A Q34773850-7AE055E6-0DEA-4346-A095-26D76AB988C5 Q35260732-88267B7A-273F-4E6C-B38B-3FB03F3609EC Q35668937-248C8F38-E07D-4BF1-8A62-644D147A3FD7 Q35669897-E7AB3BA8-7ACC-4FF6-BC85-E5608B5D3B38 Q35719883-0A1298F8-54E6-4EB3-B7BB-A47201DFF740 Q35740455-DC7C594E-2096-4B40-8A41-B1327BCDAB02 Q35925252-958EEF88-3B49-4EDE-8127-A859269CB923 Q36290238-FA9FFB11-AF40-4FF3-A039-2489064F378A Q36301512-A660EF45-3C54-4D90-9397-ABFE19A9F73C Q36561366-A03C8F2C-BFDC-4955-A327-F09EC5938D95 Q36783627-DE0ECDE6-13C9-47F2-AE59-89958EA936C1 Q37132187-B4AC5FED-CC86-4128-9B22-90391C9D4112 Q37211962-03A4D15D-BA07-4F29-BD32-225C898AF582 Q37233276-32EA3A18-2834-46B3-BB30-CCB848EFF7AC Q37644866-021F2CB4-88F1-49A8-949E-8B959DF0CDD8 Q38016511-3766CED5-57EF-49D2-8DB0-0CBB81AFFA87 Q38053983-55D0477D-D749-43F8-BF9D-7BC10C5B0599 Q38056889-299739A9-8076-4819-BD0E-2CD1099D998A Q38112468-3A9C85C4-EC48-45CB-8E1A-CDBD41855797 Q38237360-2D645CC2-1D57-4506-9DA1-BED3940FF32F Q38289041-902F5995-0165-4DCA-A05B-0CE033E225F7 Q38542092-71748896-ADE3-4E47-AFEF-E58FF6E80816 Q38890236-741DCA7B-FCBA-44B1-A3DE-38321B71A31B Q38919111-1B87FFFF-78F5-4E51-B5FD-F9EFD1618DC8 Q38968027-63F6C65D-8994-48FB-BE12-EFC09110BD77 Q39141673-1E712599-CC47-412A-907C-2507C1B4F616 Q39174431-93F40936-9F07-48A1-A0CE-2E805C32397B Q41088379-A031BE6D-64D6-40D3-9FED-3759558265EE Q41190391-99934060-3A75-4EF9-81D4-67184210D2A2

P2860

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.

http://www.wikidata.org/entity/Q34263870

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Drug response in a genetically ...... edictive of clinical efficacy.

@ast

Drug response in a genetically ...... edictive of clinical efficacy.

@en

Drug response in a genetically ...... edictive of clinical efficacy.

@nl

type

label

Drug response in a genetically ...... edictive of clinical efficacy.

@ast

Drug response in a genetically ...... edictive of clinical efficacy.

@en

Drug response in a genetically ...... edictive of clinical efficacy.

@nl

prefLabel

Drug response in a genetically ...... edictive of clinical efficacy.

@ast

Drug response in a genetically ...... edictive of clinical efficacy.

@en

Drug response in a genetically ...... edictive of clinical efficacy.

@nl

P1433

Q34263870-28BE6B86-24B0-4CA0-B6FB-4A9F0EF9C491

P1476

Q34263870-E97EDB84-BD7E-4D1E-B0DC-6A7BCF39EA59

P2093

Q34263870-0BEA1D81-E186-4320-8F85-11090F9A4D37

Q34263870-53D76788-8BAA-4FE1-9CB1-380D08541995

Q34263870-6C5A57FE-97BF-480E-83E0-1FBAB37DF220

Q34263870-7E96BDFA-D3CB-42CE-ABEA-4B75459A6111

Q34263870-C2D665C6-B320-458A-A533-5F8BEE533AFD

Q34263870-C5307B90-74B7-473C-A4A6-DEFADED696DB

Q34263870-D39ABF04-87C3-4F0C-AA94-AB2EEDFED4A5

P2860

Q34263870-174E1B02-C067-4C08-A622-EDC2E3BCB5A2

Q34263870-1EE7B451-317E-4E8C-AB0E-14F7600F91F7

Q34263870-2A82F051-EA4D-4C1D-A29D-6FCB6036587F

Q34263870-4402D541-1989-4C1C-A789-4360E5A047BE

Q34263870-4D6D09EC-3D28-4A6A-B453-E8F48FB4C3E8

Q34263870-4F91BF21-49AC-4FC9-96AB-90B6C09D614C

Q34263870-69ACCB26-23F2-41D9-85DA-CCB6B51DEE07

Q34263870-6FD5C102-D602-4131-96AB-519649D51A27

Q34263870-705AB09E-5229-46A4-9544-6E68F8B02AC8

Q34263870-82EAF066-6AB6-4215-8945-309B45F15E4F

P304

Q34263870-12AAA96F-3EB7-418B-A429-A8F93DAFCFB2

P31

Q34263870-6CB21278-FDC7-4DFD-BE21-BAADD3F77702

P356

Q34263870-1DFB260F-5AAE-408F-8DA2-B80B18F3AAA9

P407

Q34263870-27B0BB22-6B18-41C8-91C1-0288CD4432CA

P433

Q34263870-419396CD-EA46-4EE7-ABF8-2D32980D406C

P478

Q34263870-A764E0FC-067B-473C-A046-C5F8A2C0D10D

P50

Q34263870-46373981-64F5-4C49-864F-632891E1FE08

Q34263870-A29E482C-53EB-4330-834F-810D7DEFC60E

P577

Q34263870-8C3DED3C-376C-4649-A1DF-A72A5B21FC45

P698

Q34263870-8194BAFB-5FD9-4601-9314-09810F52F5A8

P932

Q34263870-92F0184F-E6FA-4C9C-A624-ECBE577C0484

P356

BLOOD-2012-02-412783

P1433

P1476

Drug response in a genetically ...... edictive of clinical efficacy.

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Geoffrey M Matthews

http://www.w3.org/2001/XMLSchema#string

Marcus Lefebure

http://www.w3.org/2001/XMLSchema#string

Marta Chesi

http://www.w3.org/2001/XMLSchema#string

P Leif Bergsagel

http://www.w3.org/2001/XMLSchema#string

Stephen E Palmer

http://www.w3.org/2001/XMLSchema#string

Victoria M Garbitt

http://www.w3.org/2001/XMLSchema#string

P2860

A low-viscosity epoxy resin embedding medium for electron microscopy

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Can the pharmaceutical industry reduce attrition rates?

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

PHASE II STUDIES OF HYDROXYUREA (NSC-32065) IN ADULTS: MULTIPLE MYELOMA AND LYMPHOMA.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

P304

376-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2012-02-412783

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

120

http://www.w3.org/2001/XMLSchema#string

P50

Ricky W Johnstone

P577

2012-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22451422

http://www.w3.org/2001/XMLSchema#string

P932

3398763

http://www.w3.org/2001/XMLSchema#string